Tetra, Pharm

Tetra Pharm Technologies bringt den CB1-Antagonisten TPT0701 zur Appetitunterdrückung in die präklinische Testphase

Published on 08/07/2025 at 18:08 | prnewswire.co.uk

Tetra Pharm Technologies Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom Denmark

View original content:https://www.prnewswire.com/news-releases/tetra-pharm-technologies-bringt-den-cb1-antagonisten-tpt0701-zur-appetitunterdruckung-in-die-praklinische-testphase-302056051.html

en | boerse | 67927894 |